PubMed Health⌕ Search

Biomedical subjects

H Maruo

Publications and source records attributed to H Maruo.

27 records · Page 2Linked to original sources
PubMed1993

[Postoperative hypophosphatemia in patients with cancer of the thoracic esophagus].

Postoperative phosphate dynamics were studied in 30 patients who underwent radical surgery for thoracic esophageal cancer and who were postoperatively nourished by total parenteral nutrition. There was a significant fall in the serum phosphate level on the 2nd and 3rd postoperative days in all patients. Postoperative hypophosphatemia was due to an increase in urinary phosphate excretion which was indicated by the fall in TRP% and TmPO4/GFR. A highly significant positive correlation was observed between the increase in urinary phosphate loss and the enhanced secretion of parathyroid hormone which was possibly triggered by surgical stress, a decrease in the serum level of calcium, the action of phosphate buffer or diuretics. All the patients except for those with postoperative pulmonary complications responded to the drop in serum phosphate by renal conservation of phosphate. A slight decrease in the serum level of phosphate was also found on the 6th postoperative day in most patients who were receiving parenteral hyperalimentation. The second fall in phosphate was due to transcellular shifts of phosphate. It is concluded that patients with postoperative pulmonary complications develop severe hypophosphatemia which should be prevented by replacement therapy with phosphate in the immediate postoperative period.

Calcium↗
PubMed1992

[Therapeutic results of intra-arterial infusion chemotherapy using an implantable reservoir on metastatic liver tumors].

Forty-four patients with unresectable liver tumors including 25 colorectal cancers, 7 gastric cancers, 6 breast cancer, and 6 other diseases, were treated by intra-arterial infusion chemotherapy using an implantable reservoir. The catheter was placed in hepatic artery via left subclavian artery or by direct insertion at laparotomy. Adriamycin, epirubicin or cisplatin were administered intermittently. Response rate was 31.8% for colorectal cancer, 42.9% for gastric cancer, and 60.0% for breast cancer, averaging 37.5% for all cases. Response in colorectal cancer tended to be higher for cases of H2, well-differentiated adenocarcinoma, and v(-). Response was also validated by survival time and changes in CEA. In a few patients, metastatic lesions could be resected after this treatment. Our results indicate that in combination with an aggressive surgical procedure, this treatment may improve the prognosis of patients with metastatic liver tumors.

Aged↗
PubMed1991

[Effects of sublethal endotoxemia to the hepatic reticuloendothelial system after massive hepatectomy].

Sublethal doses (1mg/kg) of endotoxin (ET) were intravenously administered on the first, third and fifth days after 34%, 70%, and 84% hepatectomies in rats. The same hepatectomy groups of rats without ET administration were made. Survival rates, distribution of Kupffer cells (Kc), regeneration rate of the liver weight, carbon clearance test (K value) and PTAH staining were compared between ET treated and untreated groups. Survival rates of 84% hepatectomy rats with ET injection on the 3rd postoperative day (POD) was significantly lower than those of 70% hepatectomy rats with ET on the 1st or 3rd POD. ET activated reticuloendothelial function of the non-hepatectomized and 34% hepatectomy rats, but reduced the number of the Kc in the central zone, especially in 84% hepatectomized rats. K values and the number of Kc in the central zone showed a good correlationship (r = 0.9) after 70% and 84% hepatectomies. Patchy hepatic necrosis and fibrin clots were observed histologically in the liver, kidney and spleen of rats died after ET administration. In conclusion, sublethal endotoxemia reduces the function and number of Kupffer cells in the regenerating liver and causes postoperative death in the rats with massive hepatectomy.

Animals↗
PubMed1990

[The inhibitory effect of long-acting beta-adrenergic agonists, mabuterol, clenbuterol and fenoterol on "morning dipping" in patients with asthma].

We examined the inhibitory effect of the long-acting beta-adrenergic agonists, mabuterol, clenbuterol and fenoterol on "morning dipping" in ten patients with nocturnal asthma. On the first night, as a control experiment, the subjects received no beta-adrenergic agonist. On the succeeding three nights at 8:00 PM, each subject was orally administered 50 micrograms of mabuterol, 40 micrograms of clenbuterol and 5 mg of fenoterol in a randomized, crossover fashion. Pulmonary function tests (FVC, FEV1.0, PEFR, V50 and V25) were performed at 8:00 PM (just before administration of beta-adrenergic agonist), 9:00 PM, 10:00 PM, 6:00 AM and 8:00 AM. On the night when clenbuterol was administered, there was a significant inhibition of morning dipping at 6:00 AM in FVC (p less than 0.01), FEV1.0 (p less than 0.01), PEFR (p less than 0.01), V50 (p less than 0.01) and V25 (p less than 0.05) compared with the control night. On the nights when mabuterol and fenoterol were administered, there was a significant inhibition of morning dipping at 6:00 AM in FVC (p less than 0.01) and FEV1.0 (p less than 0.01) compared with the control night. Palpitations associated with clenbuterol administration were seen in two subjects. The effect of each beta-adrenergic agonist varied inconsistently among the subjects. These results indicate that clenbuterol is the most effective in inhibiting morning dipping among the long-acting beta-adrenergic agonists examined, but individualization in the choice of beta-adrenergic agonist is mandatory in order to achieve the maximum effect.

Administration, Oral↗
PubMed1990

[Long-term follow-up studies of bronchial asthma in children. I. Prognosis and risk factors].

A questionnaire on the prognosis of bronchial asthma was sent in 1988 to 1,592 patients (1,038 males, 554 females) averaging 20 years of age after 12 years' follow up. The results were as follows: 75.6% in remission, 18.2% improved, 4.0% unchanged, 0.9% worse and 1.3% dead from asthma. The average age of onset was 2.7 years, about 1 year earlier than that in our report of 1965. The average age of remission (growing out of asthma) was 13.0 years for males and 12.3 years for females. The prognosis was significantly poorer among asthmatics with an onset age of under 2 years, with a 10-year history of asthma before the first visit to our hospital, with severe attack at the initial visit, a history of admissions for the attacks and food allergy. The asthmatic children with food allergy had a 1-year earlier onset of attack, a more severe attack at the initial visit, more eczema in infancy, and 2 or more other allergic complications than children without food allergy. We have to closely follow and care for those asthmatic children with high risk factors for an extended period.

Adolescent↗
PubMed1990

[Long-term follow up studies of bronchial asthma in children. II. Prognosis and complications, treatment and allergic evaluations].

A questionnaire on the prognosis of bronchial asthma was sent in 1988 to 1592 patients (1038 males, 554 females) averaging 20 years of age after 12 years' follow up. We reported on the prognosis and risk factors associated with asthmatic children in part I. The relation between prognosis and other allergic complications, treatment and laboratory data were investigated in this study. Eosinophil counts of more than 1000/mm3 and/or total serum IgE levels of more than 500 IU/ml (100 IU/ml in infants) indicated poor prognosis. However, the prognosis was not affected either by the allergens themselves or by the number of allergens determined by skin test and RAST. The prognosis was worse for patients with multiple allergic complications than for those without complications. Treatment may after the natural course of childhood asthma, but it has been difficult to evaluate the effect of each regimen over a long period. We compared the effect of hyposensitization (specific immunization) and non-bronchodilator antiasthmatic drugs (NBAAD), and found that hyposensitization alone gave better results than NBAAD and its combination. We had better results from hyposensitization over a period of 1 to 5 years than for less than 1 year or more than 5 years. We conclude that asthmatic children with risk factors should be kept under strict environmental control and given suitable therapeutic regimens to avoid the development of allergic diseases, the slow down of "allergic march", and to avoid intractable asthma.

Asthma↗